Pan-cancer analysis of PSCA that is associated with immune infiltration and affects patient prognosis-Reference-Cited by-同舟云学术

Pan-cancer analysis of PSCA that is associated with immune infiltration and affects patient prognosis

Published:2024-06-25 Issue:6 Volume:19 Page:e0298469
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wang Chenxing,Zhu Xingjia,Zheng Ming,Chen Yixun,Jiang Rui,He Xinyi,Liu Zongheng,Lu Zhichao,Wang Ziheng^ORCID,Yang Yang^ORCID

Abstract

Prostate stem cell antigen (PSCA) is associated with disease progression, promotion of angiogenesis, invasion, metastasis and immune evasion in cancer. However, its expression pattern and diagnostic and prognostic potential have not been thoroughly analysed from a pan-cancer perspective. This study aimed to examine the effects of PSCA on the prognosis and inflammatory cell infiltration patterns of various cancer types. We analysed the relationship between PSCA expression and immunological subtypes in tumor microenvironment (TME) and the role of molecular subtypes, potentially promising immune biomarkers and tumour-infiltrating lymphocytes (TILs) in various cancer types, especially lung adenocarcinoma (LUAD). In addition, we investigated the prognostic significance of PSCA expression in LUAD. The co-expression network of PSCA was found to be mainly involved in the regulation of immune responses and antigen processing and expression and was significantly enriched in pathological and substance metabolism-related pathways in cancer. Altogether, this study reveals that PSCA is a promising target for immunotherapy in patients with cancer.

Funder

Science and Technology Project of Nantong City

Publisher

Public Library of Science (PLoS)

Reference30 articles.

1. K Y, M S, E M, et al.—Inferring tumour purity and stromal and immune cell admixture from expression. D—101528555 (- 2041–1723 (Electronic)):- 2612.

2. L L, E L, L L, et al.—PSCA regulates IL-6 expression through p38/NF-κB signaling in prostate cancer.—Prostate 2017 Oct;77(14):1389–1400 101002/pros23399 Epub 2017 Aug 28 (- 1097–0045 (Electronic)):- 1389–400.

3. ML M, MA T, Y K, et al.—Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without. D—8101368 (- 0270–4137 (Print)):- 139–51.

4. V L, F B, A S, et al.—Gene identification for risk of relapse in stage I lung adenocarcinoma patients. D—101532965 (- 1949–2553 (Electronic)):- 30561–74.

5. P G-H, Id O, R R-O, et al.—Polymorphisms PSCA rs2294008, IL-4 rs2243250 and MUC1 rs4072037 are associated. D—0403234 (- 1573–4978 (Electronic)):- 9239–43.